Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avax Technologies has concluded its Phase I/II study for the treatment of patients with melanoma. The study was designed to evaluate four doses of MVax with dose defined by the number of cells injected in each vaccine.
Subscribe to our email newsletter
The doses tested in the study were high, medium, low and zero. All dosages were administered according to a previously developed optimum schedule, which included an induction dose without adjuvant followed by low dose cyclophosphamide and then six doses admixed with the immunological adjuvant, BCG. Endpoints of the study were safety and an immunological endpoint of delayed-type hypersensitivity (DTH), which is a T-cell-mediated immune response to autologous melanoma cells.
The high-dose arm of vaccine was highly effective immunologically with positive DTH responses to hapten-modified autologous melanoma cells observed in 22/29 (76%) patients following a course of MVax; baseline DTH responses were negative, as a condition of enrollment. In contrast, the zero-dose arm was ineffective. Linear regression analysis of DTH responses of all evaluable patients showed a clear dose-response relationship when DTH responses for each patient were plotted against the MVax dose received.
The safety profile of MVax appeared to be very favorable. There were no serious adverse events attributed to MVax.